A new study finds that a significant portion of older adults with mild cognitive impairment or dementia develop new cardiovascular diagnoses each year that may require treatment with anticoagulants or thrombolytics—medications that doctors often avoid during anti-amyloid monoclonal antibody therapy for Alzheimer’s disease due to increased bleeding risk.
This article was originally published on MedicalXpress.com

